Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>AstraZeneca has agreed to acquire exclusive global development and commercialization rights to Zegfrovy, a lung cancer treatment developed by China’s Dizal Pharmaceutical, in a transaction worth up to $1.5 billion.</li>
<li>The company will pay $600 million upfront, with as much as $900 million in additional payments linked to specified milestones, while Dizal will also receive tiered royalties on future sales.</li>
<li>Zegfrovy is already approved in the United States and China for adults with locally advanced or metastatic non-small cell lung cancer, giving AstraZeneca an asset that has moved beyond the earliest and riskiest stages of drug development.</li>
</ul>


AstraZeneca has agreed to acquire exclusive global development and commercialization rights to Zegfrovy, a lung cancer treatment developed by China’s Dizal Pharmaceutical, in a transaction worth up to $1.5 billion.
The company will pay $600 million upfront, with as much as $900 million in additional payments linked to specified milestones, while Dizal will also receive tiered royalties on future sales.
Zegfrovy is already approved in the United States and China for adults with locally advanced or metastatic non-small cell lung cancer, giving AstraZeneca an asset that has moved beyond the earliest and riskiest stages of drug development.


AstraZeneca’s $1.5 Billion Cancer Bet Could Change Everything—But Is It Worth The Risk?